Ocular Therapeutix Inc (OCUL)
5.80
0.00 (0.00%)
USD |
NASDAQ |
May 24, 10:09
Ocular Therapeutix Research and Development Expense (Quarterly): 20.74M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 20.74M |
December 31, 2023 | 16.20M |
September 30, 2023 | 15.02M |
June 30, 2023 | 15.09M |
March 31, 2023 | 14.75M |
December 31, 2022 | 13.54M |
September 30, 2022 | 13.72M |
June 30, 2022 | 13.10M |
March 31, 2022 | 13.10M |
December 31, 2021 | 12.58M |
September 30, 2021 | 12.72M |
June 30, 2021 | 13.86M |
March 31, 2021 | 10.93M |
December 31, 2020 | 7.624M |
September 30, 2020 | 6.951M |
June 30, 2020 | 8.021M |
March 31, 2020 | 6.098M |
December 31, 2019 | 10.12M |
September 30, 2019 | 10.24M |
June 30, 2019 | 9.414M |
March 31, 2019 | 11.32M |
December 31, 2018 | 10.26M |
September 30, 2018 | 9.685M |
Date | Value |
---|---|
June 30, 2018 | 8.745M |
March 31, 2018 | 8.227M |
December 31, 2017 | 7.908M |
September 30, 2017 | 8.126M |
June 30, 2017 | 8.117M |
March 31, 2017 | 6.729M |
December 31, 2016 | 7.328M |
September 30, 2016 | 5.686M |
June 30, 2016 | 6.978M |
March 31, 2016 | 7.073M |
December 31, 2015 | 6.886M |
September 30, 2015 | 8.263M |
June 30, 2015 | 6.743M |
March 31, 2015 | 4.719M |
December 31, 2014 | 5.148M |
September 30, 2014 | 4.482M |
June 30, 2014 | 4.292M |
March 31, 2014 | 4.958M |
December 31, 2013 | 2.842M |
September 30, 2013 | 2.784M |
June 30, 2013 | 2.404M |
March 31, 2013 | 2.487M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.098M
Minimum
Mar 2020
20.74M
Maximum
Mar 2024
12.19M
Average
12.91M
Median
Research and Development Expense (Quarterly) Benchmarks
Amgen Inc | 1.343B |
Assertio Holdings Inc | 0.733M |
CytomX Therapeutics Inc | 22.05M |
EyePoint Pharmaceuticals Inc | 30.14M |
Cormedix Inc | 0.8374M |